Atria Investments Inc Purchases 1,442 Shares of Regeneron Pharmaceuticals, Inc. $REGN

by · The Cerbat Gem

Atria Investments Inc lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 11,469 shares of the biopharmaceutical company’s stock after acquiring an additional 1,442 shares during the quarter. Atria Investments Inc’s holdings in Regeneron Pharmaceuticals were worth $6,021,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. PGGM Investments boosted its stake in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after purchasing an additional 51,900 shares during the period. Founders Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares during the period. Sepio Capital LP boosted its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 842 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after purchasing an additional 955 shares during the period. Finally, Generate Investment Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $6,300,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $651.80 on Friday. The business has a 50 day moving average of $581.80 and a 200 day moving average of $565.22. The company has a market capitalization of $69.08 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $883.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.46 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Bank of America raised their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a report on Wednesday. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday. Cantor Fitzgerald raised their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $802.36.

Read Our Latest Stock Analysis on Regeneron Pharmaceuticals

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.02% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).